In May 2023, former health minister Lord James OShaughnessy acknowledged in a report that there were many issues with the UKs clinical trial industry. The report showed that the country fell from fourth to tenth globally for trial initiation, with a big drop in the number of Phase III trials initiated.

At the same time, the UKs National Health Service (NHS) has been under extreme pressure with staffing woes, including the recent junior doctor strikes and financial difficulties impeding clinicians ability to participate in research, especially in more demanding cell and gene therapy trials.

With a snap general election now looming on 4 July and the NHS being one of the top concerns for voters, it is more important than ever for political parties to set out their manifesto including how they are going to facilitate research and support the NHS.

The UK Conservative government has tried to improve the countrys ability to develop cell and gene therapies, with a $10m grant in March 2023 for the NHS Blood and Transplant (NHSBT) to open a facility to develop and manufacture new gene and cell therapies called the Clinical Biotechnology Centre (CBC).

Funds have also been provided to several companies through the Life Sciences Innovative Manufacturing Fund (LSIMF) grants, including 151m for Pharmaron and 14m for Touchlight for cell and gene therapy development and manufacturing.

On top of all this, the UKs National Institute for Health and Care Research (NIHR) has announced a 17.9m investment in the Advanced Therapy Treatment Centre Network (ATTC Network).

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Your download email will arrive shortly

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

Country * UK USA Afghanistan land Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Cte d"Ivoire Croatia Cuba Curaao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Runion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo

Industry * Academia & Education Aerospace, Defense & Security Agriculture Asset Management Automotive Banking & Payments Chemicals Construction Consumer Foodservice Government, trade bodies and NGOs Health & Fitness Hospitals & Healthcare HR, Staffing & Recruitment Insurance Investment Banking Legal Services Management Consulting Marketing & Advertising Media & Publishing Medical Devices Mining Oil & Gas Packaging Pharmaceuticals Power & Utilities Private Equity Real Estate Retail Sport Technology Telecom Transportation & Logistics Travel, Tourism & Hospitality Venture Capital

Tick here to opt out of curated industry news, reports, and event updates from Clinical Trials Arena.

Submit and download

A year on from Lord OShaughnessys report and despite the governments investment in the industry, the UK is still struggling to contribute to cell and gene therapy trials says haematologist and chief medical officer of stem cell charity Anthony Nolan Dr Robert Danby. Danby speaks exclusively to the Clinical Trials Arena about the difficulties facing the NHS in contributing to cell and gene therapy research.

Robert Danby (RD): The UK Government has committed to implementing all of Lord OShaughnessys recommendations, and we have seen some progress in the year since. Average trial approval and set-up times have been reduced. The number of people taking part in industry clinical studies is rising. According to the Department of Health and Social Care, 82% of commercial studies are on track.

Despite this, there is still more work to do. A thriving clinical research environment depends on an NHS that has the resources and workforce to support it with trials relying on the UKs network of clinicians, nurses, allied health professionals, statisticians, data managers, and more.

But as organisations such as Cancer Research UK have pointed out, were still a long way from NHS staff having the capacity to prioritise research. A survey of health care professionals revealed nearly four in five clinical researchers described lack of capacity as a substantial or extreme barrier to their work. It means clinical research is at risk of being seen as a nice-to-have, rather than an essential mechanism for bringing new and potentially life-saving therapies to the UK.

The OShaughnessy review said less about tackling the barriers patients face to getting onto a clinical trial. We need to think more ambitiously about the diversity of trial participants, to ensure no groups miss out on the potential improvements to care they offer. We also need to see investment in the real-world data landscape that can play such a pivotal role in advanced cell and gene therapies research.

RD: While we have seen commercial trial capacity increase in the last year, cell and gene therapies present additional research challenges that require a concerted effort to overcome. As a haematologist and in my work at Anthony Nolan, I see this close up.

Blood cancers and other haematological disorders are at the forefront of the oncoming wave of new cell and gene therapies. With over 50 years experience in cell therapies, both allogeneic and autologous haematopoietic cell transplantation, haematology is one of the few medical fields with the necessary skills and expertise to deliver clinical research into these potentially transformative treatments.

But the UKs haematology departments are not yet equipped, or resourced, to deliver this next wave. For example, cell and gene therapies are reliant on apheresis technology to collect the cells which form the basis of new engineered treatments. But current infrastructure is struggling to cope with basic clinical needs for standard indications, never mind additional requirements for therapy development.

Challenges to recruit to cell and gene therapy trials and rigorous regulatory pathways also contribute to the strain faced by NHS teams expected to deliver both basic care and clinical research. And as cell and gene therapy trials move into other areas of medicine like solid cancers or autoimmune diseases, there will need to be a massive increase in resources, training, and education across the breadth of the NHS.

In order to sustain the development of future cell and gene therapies, long-term investment into NHS capacity, education and training is essential. A more streamlined journey from research to regulatory approval and implementation, that is appropriate for the specific requirements of cell and gene therapies, is also needed.

RD: Brexit has compounded many of the issues affecting the UKs position in the global clinical research market. In my field of haematology, the well-recorded loss of NHS and academic staff due to Brexit has had major implications on our ability to carry out not only day-to-day care but also clinical research.

Weve also heard that differences in the regulatory framework and bodies between the UK and Europe post-Brexit have made the industry reluctant to start trials in the UK because implementation into routine care use looks too time-consuming and challenging.

RD: Accelerating Clinical Trials (ACT) is an innovative self-sustaining model to facilitate the delivery of clinical trials for blood cancers and blood disorders.

The ACT operational hub provides services to industry-sponsored commercial trials including access to a national network of recruitment sites, clinical research expertise and operational support and reinvests the income into non-profit academic investigator-led trials.

The OShaughnessy review highlighted that in its first 12 months, ACT attracted investment from two international pharmaceutical companies to deliver practice-informing blood cancer trials. With the income, ACT works with two major national trial acceleration networks which have recruited more than 2,500 patients in recent years, to the benefit of both patients and the UK life sciences sector.

Earlier this year, Anthony Nolan announced its 1m investment into the programme.

RD: We recognise we are seeing a revolution in cell and gene therapies, and the opportunity in the UK is huge. Our nationalised health care system, with strong links to academia, and healthcare data mean there is enormous potential for UK patients to be some of the first to benefit from these innovative and potentially curative therapies. But only if we act now to address issues in NHS capacity, invest in world-leading data systems and simplify the pathway to therapy implementation.

Editorial content is independently produced and follows thehighest standardsof journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Give your business an edge with our leading industry insights.

Read the original:
NHS investment critical to drive cell and gene therapy research - Clinical Trials Arena

Comments are closed.